Emgality demonstrated a consistent safety profile across six Phase 3 studies in migraine and episodic cluster headache (N=3724)1-4

Lilly continues to monitor the safety data of Emgality in the general population.

Download savings cards to help eligible patients on Emgalityc

cGovernmental beneficiaries excluded; terms and conditions apply.

Discover what Emgality can do for your patients with 4 or more unpredictable MHDs per month1


  1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.
  2. Bangs ME, Kudrow D, Wang S, et al. Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies. BMC Neurol. 2020;20:90. doi:10.1186/s12883-020-1609-7.
  3. Mulleners WM, Kim B, Láinez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19:814-825.
  4. Data on File. Lilly USA, LLC. DOF-GZ-US-0107.
  5. Data on File. Lilly USA, LLC. DOF-GZ-US-0008.
  6. Data on File. Lilly USA, LLC. DOF-GZ-US-0007.
  7. Data on File. Lilly USA, LLC. DOF-GZ-US-0026.
  8. Oakes TM, Kovacs R, Rosen N, et al. Evaluation of cardiovascular outcomes in adult patients with episodic or chronic migraine treated with galcanezumab: data from three phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. Headache. 2020;60:110-123.
  9. Data on File. Lilly USA, LLC. DOF-GZ-US-0165.
  10. Camporeale A, Kudrow D, Sides R, et al. A phase 3, long-term, open-label safety study of galcanezumab in patients with migraine. BMC Neurol. 2018;18(1):188. doi:10.1186/s12883-018-1193-2.
  11. Data on File. Lilly USA, LLC. DOF-GZ-US-0137.
  12. Data on File. Lilly USA, LLC. DOF-GZ-US-0139.
  13. Data on File. Lilly USA, LLC. DOF-GZ-US-0140.


Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.



Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache